[Complement activity in leukemic patients].
The in vitro test of heterologous anti-leukaemic sera against human leukaemic cells resulted in the serum of leukaemic patients being able to produce a lysis of leukaemic cells in the leukaemic phase as well as in remission when specific heterologous antibodies were present.
D000918:Antibody Specificity; D000961:Antilymphocyte Serum; D003165:Complement System Proteins / Q000378:metabolism*; D007938:Leukemia / Q000276:immunology*; D007945:Leukemia, Lymphoid / Q000276:immunology; D015470:Leukemia, Myeloid, Acute / Q000276:immunology
D000961:Antilymphocyte Serum; D003165:Complement System Proteins
Komplementaktivität bei Leukämiepatienten.